Press Releases

Date Title and Summary
Toggle Summary Accuray and RaySearch Announce Long-Term Collaboration Agreement Regarding the RayCare® Oncology Information System
SUNNYVALE, Calif. and STOCKHOLM , July 13, 2015 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY) and RaySearch Laboratories AB (publ) (NASDAQ OMX Stockholm: RAY B) announced today they have signed a long-term collaboration agreement which will allow Accuray to co-market and offer the RayCare ®
Toggle Summary Accuray and RaySearch Announce Second Long-Term Collaboration Agreement
RayStation® will be Extended to Include Treatment Planning for the TomoTherapy® and CyberKnife® Systems SUNNYVALE, Calif. , and STOCKHOLM , Oct. 5, 2015 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) and RaySearch Laboratories AB (publ) (NASDAQ OMX Stockholm: RAY B) announced today that they
Toggle Summary Accuray and Siemens Form Strategic Alliance to Expand Global Distribution of CyberKnife and Share Technology
Siemens to Expand Distribution of CyberKnife Systems As Part of its Global Product Portfolio Accuray and Siemens to Create Long-Term Research and Development Relationship to Identify Potential New Technologies and Products SUNNYVALE, Calif., June 9, 2010 /PRNewswire via COMTEX/ --Accuray (Nasdaq:
Toggle Summary Accuray and the German Cancer Research Center Sign Master Research and Collaboration Agreement
Latest Collaboration with Leading Research Institution Continues Partnership in New Technology Development ­ SUNNYVALE, Calif. , May 22, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the signing of a multi-year master research and
Toggle Summary Accuray Announces 500th TomoTherapy® System Installation
Milestone System to Handle Full Patient Load for New, Integrated Cancer Center in Scottsdale, Arizona SUNNYVALE, Calif. , May 22, 2014 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the installation of its 500 th TomoTherapy® System at the grand opening of Palo Verde Cancer
Toggle Summary Accuray Announces Additions to Board of Directors
SUNNYVALE, Calif. , Sept. 15 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Accuray's Board of Directors has appointed Louis J. Lavigne, Jr. and Dennis L. Winger as members of the company's Board of Directors.
Toggle Summary Accuray Announces Agreement with Brainlab to Expand CyberKnife® Platform Treatment Capabilities for the Neuro-Radiosurgery Market
Interoperability between Brainlab and Accuray planning systems using Snke OS, an enterprise health tech platform SUNNYVALE, Calif. , Oct. 28, 2020 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a pioneer in the robotic stereotactic radiosurgery (SRS) field announced today a collaboration with
Toggle Summary Accuray Announces Approval of the Tomo® C Radiation Treatment Delivery System by China's National Medical Products Administration
MADISON, Wis. , Oct. 3, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo ® C radiation therapy system for the Type B market has been approved by the Chinese National Medical Products Administration (NMPA).
Toggle Summary Accuray Announces Conference Call to Discuss Amendments to Fiscal Third Quarter 2007 Financial Results
SUNNYVALE, Calif., May 14 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced it will conduct a live conference call and webcast for investors and analysts to discuss announced amendments to the Company's fiscal third quarter
Toggle Summary Accuray Announces Convertible Notes Exchange and Subscription
SUNNYVALE, Calif. , May 6, 2021 /PRNewswire/ --  Accuray Incorporated  (NASDAQ: ARAY) today announced that it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2022 (the "2022 Notes") to exchange an aggregate of $82.1 million

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.